COVID-19 Clinical Trial
— APPEX-19Official title:
Awake Prone Position for Early Hypoxemia in COVID-19
NCT number | NCT04344587 |
Other study ID # | H-40070 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 23, 2020 |
Est. completion date | May 7, 2021 |
Verified date | October 2021 |
Source | Boston University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Prone positioning is a well studied and validated treatment for severe acute respiratory distress syndrome (ARDS), however there are no randomized studies on the use of prone positioning in the non-intubated patient. It is unknown if this intervention would be helpful in preventing further respiratory deterioration in terms of increasing supplemental oxygen requirements, endotracheal intubation, and ICU admission. The Awake Prone Position for Early hypoxemia in COVID-19 (APPEX-19) Study is a pragmatic adaptive randomized controlled unblinded trial. APPEX-19 randomizes non-ICU patients with COVID-19 or who are under evaluation for COVID-19 to lie in a prone position (i.e, with their stomach and chest facing down) or to usual care.
Status | Completed |
Enrollment | 305 |
Est. completion date | May 7, 2021 |
Est. primary completion date | May 7, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Assigned to or admitted to a COVID-19 ward team at a participating site (these teams only admit patients who are under investigation for COVID-19 or who have confirmed COVID-19 infection) via the emergency department (ED) within the last 24 hours - Have access to their own functioning smartphone in the hospital room - English or Spanish-speaking - Ability to read simple instructions and answer simple written questions Exclusion Criteria: Baseline patient factors - Inability to operate the hospital bed - Inability to lie flat comfortably - Inability to lie flat without shortness of breath - Inability to turn over independently Medical comorbidities - Hemoptysis in the last 2 days - Prior lung transplant - Dementia Acute issues - Deep venous thrombosis treated for less than 2 days - Unstable spine, femur, or pelvic fractures - Mean arterial pressure lower than 65 mmHg - Receiving =6 liters per minute of supplemental oxygen via nasal cannula, nasal pendant, or shovel mask - Receiving supplemental oxygen via more aggressive methods (e.g. Venturi mask or non-rebreather mask) Recent interventions - Chest tube in place - Tracheal surgery or sternotomy during the previous 15 days - Serious facial trauma or facial surgery during the previous 15 days - Cardiac pacemaker inserted in the last 2 days Other - Pregnancy - Comfort measures only status - Prisoner |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitario La Paz | Madrid | |
United States | University of Michigan | Ann Arbor | Michigan |
United States | Piedmont Atlanta | Atlanta | Georgia |
United States | Boston Medical Center | Boston | Massachusetts |
United States | St. Joseph's Hospital National Jewish Health | Denver | Colorado |
United States | Michael E. DeBakey Veteran Affairs Medical Center | Houston | Texas |
United States | University of Iowa Hospitals and Clinics | Iowa City | Iowa |
United States | University of Kansas Medical Center | Kansas City | Kansas |
United States | Long Beach Medical Center - MemorialCare | Long Beach | California |
United States | Creighton University | Omaha | Nebraska |
United States | VCU Medical Center | Richmond | Virginia |
United States | Alvarado Hospital | San Diego | California |
United States | MedStar Georgetown University Hospital | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Boston University |
United States, Spain,
Garcia MA, Rampon GL, Doros G, Jia S, Jagan N, Gillmeyer K, Berical A, Hudspeth J, Ieong M, Modzelewski KL, Schechter-Perkins EM, Ross CS, Rucci JM, Simpson S, Walkey AJ, Bosch NA. Rationale and Design of the Awake Prone Position for Early Hypoxemia in COVID-19 Study Protocol: A Clinical Trial. Ann Am Thorac Soc. 2021 Sep;18(9):1560-1566. doi: 10.1513/AnnalsATS.202009-1124SD. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in respiratory status | Change in respiratory status will be defined as:1) admission to the ICU and/or a 2) an increase in supplemental oxygen delivery (defined as an increase in oxygen delivery rate of =2 liter per minute compared to the oxygen delivery rate at the time of intervention or usual care text message that is sustained for =12 or more hours OR the switch to an oxygen delivery method that increases the level of supplemental oxygen. | up to 30 days | |
Secondary | Length of time participant spends in the prone position | Length of time in the prone position will be assessed from the smartphone survey and measured in categories of no time, up to 6 hours, 6 hours to 11 hours, 12 hours or more. | up to 30 days | |
Secondary | Length of time participant spends in the supine position | Length of time in the supine/lying on back position will be assessed from the smartphone survey and measured in categories of no time, up to 6 hours, 6 hours to 11 hours, 12 hours or more. | up to 30 days | |
Secondary | Length of time participant spends lying on side | Length of time lying on side will be assessed from the smartphone survey and measured in categories of no time, up to 6 hours, 6 hours to 11 hours, 12 hours or more. | up to 30 days | |
Secondary | Length of time participant spends sitting up | Length of time sitting up will be assessed from the smartphone survey and measured in categories of no time, up to 6 hours, 6 hours to 11 hours, 12 hours or more. | up to 30 days | |
Secondary | Length of time participant spends standing or walking | Length of time standing or walking will be assessed from the smartphone survey and measured in categories of no time, up to 6 hours, 6 hours to 11 hours, 12 hours or more. | up to 30 days | |
Secondary | Dyspnea or difficult/labored breathing | Dyspnea will be assessed by the modified Borg Dyspnea Score (10-point ordinal scale) from 1= nothing at all to 10= maximal. Higher scores indicate more dyspnea. | up to 30 days | |
Secondary | Discomfort with proning | Discomfort with proning (4-point ordinal scale: very comfortable, somewhat comfortable, somewhat uncomfortable, very uncomfortable) | up to 30 days | |
Secondary | Length of hospital stay | Total number of days hospitalized will be abstracted from the electronic medical record. | up to 30 days | |
Secondary | Invasive mechanical ventilation | Invasive mechanical ventilation will be abstracted from the electronic medical record. | up to 30 days | |
Secondary | Loss of IV access as a consequence of turning in bed | Loss of IV access as a consequence of turning in bed will be reported by participant using monitoring surveys | up to 30 days | |
Secondary | Acute respiratory distress syndrome (ARDS) diagnosis | ARDS diagnosis will be abstracted from the electronic medical record | up to 30 days | |
Secondary | Hospital mortality | Hospital mortality will be abstracted from the electronic medical record | up to 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|